Tag
The ELZA-sub400 protocol demonstrates safe and effective high-fluence corneal cross-linking tailored for ultrathin keratoconus corneas, halting ectasia progression in most treated eyes at 12 months with no endothelial damage.
This review synthesizes evidence linking cumulative atopic diseases—including asthma, atopic dermatitis, and allergic rhinitis—to keratoconus risk, highlighting a dose-dependent association and the role of healthcare utilization in case asc
This article examines disparities in access to corneal cross-linking (CXL) for keratoconus patients in the US, highlighting challenges posed by high costs, insurance limitations, and the transition from Photrexa® to Epioxa™.
